We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Masimo PVI: Efficient Predictor for Fluid Optimization
Read MoreHide Full Article
Masimo Corporation (MASI - Free Report) , global leader in innovative non-invasive monitoring technologies, recently announced the effectiveness and clinical utility of Masimo Pleth Variability Index (PVI) for adult patients undergoing major abdominal surgery. Masimo’s share price increased 2.1% to close at $56.82 following the news.
Masimo PVI is a non-invasive guide to fluid optimization and a measure of the dynamic changes in the Perfusion Index (PI) which occur during one or more complete respiratory cycles.
Investigation of Masimo PVI by researchers at Cairo University revealed impressive level of fluid responsiveness in 60 adult ‘elective abdominal surgical patients’ during the study, making the index a trustworthy and an efficient predictor. Notably, researchers have noticed that the baseline value of Masimo PVI was significantly higher in ‘fluid responders’ compared to ‘fluid non-responders’.
In this regard we note that, Masimo PVI had also shown positive results for patients undergoing ‘liver transplantation’ earlier this year.
Our Take
Masimo is riding high on robust business prospects as projected by the impressive share price movement, which also represents a strong one-year return of 38%, better than the S&P 500’s 7.8% over the same time frame. In fact, the company is well set to gain from its series of current developments that include the release of encouraging SpHb study data for non-invasive hemoglobin monitoring and the amendment of the royalty agreement with Nellcor.
We believe that the recent announcement, accompanied by the slew of encouraging developments, should help Masimo fortify its market position going ahead.
Key Picks
Currently, Masimo has a Zacks Rank #1 (Strong Buy).
Other favorably ranked stocks in the broader medical sector include ANI Pharmaceuticals Inc. (ANIP - Free Report) , Halyard Health Inc and The Advisory Board Company . Notably, all the three stocks sport a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Masimo PVI: Efficient Predictor for Fluid Optimization
Masimo Corporation (MASI - Free Report) , global leader in innovative non-invasive monitoring technologies, recently announced the effectiveness and clinical utility of Masimo Pleth Variability Index (PVI) for adult patients undergoing major abdominal surgery. Masimo’s share price increased 2.1% to close at $56.82 following the news.
Masimo PVI is a non-invasive guide to fluid optimization and a measure of the dynamic changes in the Perfusion Index (PI) which occur during one or more complete respiratory cycles.
Investigation of Masimo PVI by researchers at Cairo University revealed impressive level of fluid responsiveness in 60 adult ‘elective abdominal surgical patients’ during the study, making the index a trustworthy and an efficient predictor. Notably, researchers have noticed that the baseline value of Masimo PVI was significantly higher in ‘fluid responders’ compared to ‘fluid non-responders’.
MASIMO CORP Price
MASIMO CORP Price | MASIMO CORP Quote
In this regard we note that, Masimo PVI had also shown positive results for patients undergoing ‘liver transplantation’ earlier this year.
Our Take
Masimo is riding high on robust business prospects as projected by the impressive share price movement, which also represents a strong one-year return of 38%, better than the S&P 500’s 7.8% over the same time frame. In fact, the company is well set to gain from its series of current developments that include the release of encouraging SpHb study data for non-invasive hemoglobin monitoring and the amendment of the royalty agreement with Nellcor.
We believe that the recent announcement, accompanied by the slew of encouraging developments, should help Masimo fortify its market position going ahead.
Key Picks
Currently, Masimo has a Zacks Rank #1 (Strong Buy).
Other favorably ranked stocks in the broader medical sector include ANI Pharmaceuticals Inc. (ANIP - Free Report) , Halyard Health Inc and The Advisory Board Company . Notably, all the three stocks sport a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>